Data / Drug companies / Biocon Biologics Inc.
Biocon Biologics Inc.: 24 products in the FDA NDC directory, labeler code 83257
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Biocon Biologics Inc. (labeler code 83257) lists 24 products in the FDA National Drug Code Directory, covering 10 finished drugs by generic name. By type: 24 prescription drugs. Its main marketing category is biologics (BLA). The newest product started marketing on November 3, 2026.
The request: Watch Biocon Biologics Inc. (FDA labeler code 83257): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 83257
- Products in commercial distribution
- 24
- Packages
- 25
- Finished drugs by generic name
- 10
- Prescription products
- 24
- Over the counter products
- 0
- Flagged as original packager
- 18 of 18 products that carry the flag
- Started marketing in the last 12 months
- 4
- Products with a marketing end date set
- 2
- Earliest marketing start
- July 28, 2023
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Biologics (BLA) | 24 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 24 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Insulin glargine-yfgn | 4 | 2 |
| Ustekinumab | 4 | 2 |
| Adalimumab-fkjp | 3 | 1 |
| Trastuzumab-dkst | 3 | 1 |
| Bevacizumab-nwgd | 2 | 1 |
| Aflibercept-jbvf | 2 | 1 |
| Insulin aspart-xjhz | 2 | 1 |
| Denosumab-kyqq | 2 | 1 |
| Pegfilgrastim-jmdb | 1 | 1 |
| Water | 1 | 40 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 12 | 50% |
| Injection | 5 | 20.8% |
| Kit | 4 | 16.7% |
| Injection, powder, lyophilized, for solution | 2 | 8.3% |
| Solution | 1 | 4.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Yesafili | 83257-013 | Injection, solution | Biologics (BLA) | November 3, 2026 |
| Yesafili | 83257-035 | Injection, solution | Biologics (BLA) | August 3, 2026 |
| Aukelso | 83257-030 | Injection | Biologics (BLA) | January 5, 2026 |
| Bosaya | 83257-029 | Injection | Biologics (BLA) | January 5, 2026 |
| Kirsty | 83257-008 | Injection, solution | Biologics (BLA) | September 15, 2025 |
| Kirsty | 83257-007 | Injection, solution | Biologics (BLA) | September 15, 2025 |
| INSULIN DILUTING MEDIUM FOR Kirsty | 83257-006 | Injection, solution | Biologics (BLA) | September 15, 2025 |
| Jobevne | 83257-010 | Injection | Biologics (BLA) | April 10, 2025 |
| Jobevne | 83257-009 | Injection | Biologics (BLA) | April 10, 2025 |
| Yesintek | 83257-026 | Solution | Biologics (BLA) | February 22, 2025 |
| Yesintek | 83257-025 | Injection, solution | Biologics (BLA) | February 22, 2025 |
| Yesintek | 83257-024 | Injection, solution | Biologics (BLA) | February 22, 2025 |
| Yesintek | 83257-023 | Injection, solution | Biologics (BLA) | February 22, 2025 |
| Adalimumab | 83257-022 | Kit | Biologics (BLA) | April 15, 2024 |
| Adalimumab | 83257-021 | Kit | Biologics (BLA) | April 15, 2024 |
| Adalimumab | 83257-020 | Kit | Biologics (BLA) | April 15, 2024 |
| Fulphila | 83257-005 | Injection | Biologics (BLA) | October 1, 2023 |
| Ogivri | 83257-004 | Kit | Biologics (BLA) | October 1, 2023 |
| Ogivri | 83257-003 | Injection, powder, lyophilized, for solution | Biologics (BLA) | October 1, 2023 |
| Ogivri | 83257-001 | Injection, powder, lyophilized, for solution | Biologics (BLA) | October 1, 2023 |
| Insulin Glargine | 83257-015 | Injection, solution | Biologics (BLA) | July 28, 2023 |
| Insulin Glargine | 83257-014 | Injection, solution | Biologics (BLA) | July 28, 2023 |
| Semglee | 83257-012 | Injection, solution | Biologics (BLA) | July 28, 2023 |
| Semglee | 83257-011 | Injection, solution | Biologics (BLA) | July 28, 2023 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.